ImmunoGen Future Growth
Future criteria checks 2/6
ImmunoGen is forecast to grow earnings and revenue by 54.6% and 48.8% per annum respectively while EPS is expected to grow by 53.7% per annum.
Key information
54.6%
Earnings growth rate
53.7%
EPS growth rate
| Biotechs earnings growth | 42.7% |
| Revenue growth rate | 48.8% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | n/a |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | 256 | -160 | -173 | -145 | 7 |
| 12/31/2023 | 126 | -261 | -234 | -211 | 10 |
| 12/31/2022 | 85 | -242 | -302 | -230 | 10 |
| 9/30/2022 | 96 | -201 | -217 | -215 | N/A |
| 6/30/2022 | 89 | -161 | -187 | -186 | N/A |
| 3/31/2022 | 92 | -129 | -167 | -166 | N/A |
| 12/31/2021 | 70 | -139 | -171 | -169 | N/A |
| 9/30/2021 | 128 | -71 | -116 | -115 | N/A |
| 6/30/2021 | 137 | -56 | -112 | -111 | N/A |
| 3/31/2021 | 135 | -49 | -97 | -95 | N/A |
| 12/31/2020 | 132 | -44 | -80 | -79 | N/A |
| 9/30/2020 | 91 | -71 | -121 | -120 | N/A |
| 6/30/2020 | 86 | -70 | -125 | -124 | N/A |
| 3/31/2020 | 87 | -89 | -128 | -127 | N/A |
| 12/31/2019 | 82 | -104 | -91 | -88 | N/A |
| 9/30/2019 | 51 | -151 | -101 | -97 | N/A |
| 6/30/2019 | 48 | -176 | -107 | -102 | N/A |
| 3/31/2019 | 42 | -174 | -113 | -106 | N/A |
| 12/31/2018 | 53 | -169 | -172 | -166 | N/A |
| 9/30/2018 | 79 | -140 | -159 | -155 | N/A |
| 6/30/2018 | 77 | -150 | -71 | -69 | N/A |
| 3/31/2018 | 107 | -117 | -11 | -9 | N/A |
| 12/31/2017 | 115 | -96 | 7 | 8 | N/A |
| 9/30/2017 | 90 | -117 | 0 | 1 | N/A |
| 6/30/2017 | 89 | -105 | -95 | -93 | N/A |
| 3/31/2017 | 57 | -142 | -153 | -150 | N/A |
| 12/31/2016 | 49 | -157 | -149 | -143 | N/A |
| 9/30/2016 | 53 | -156 | -149 | -141 | N/A |
| 6/30/2016 | 60 | -145 | N/A | -124 | N/A |
| 3/31/2016 | 65 | -129 | N/A | -120 | N/A |
| 12/31/2015 | 57 | -119 | N/A | -86 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMU's revenue (48.8% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: IMU's revenue (48.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMU's Return on Equity is forecast to be high in 3 years time